Table 1.

iTTP associated with COVID-19 infection: comparison of cases described in the literature and our case

Reference	Gender/age, years	TTP diagnosis time relative to SARS-CoV-2 infection	SARS-CoV-2 swab	COVID 19 disease severity	TTP treatment	TTP course
Our case	Female/62	Concomitant	Positive	Mild	PEX (n = 5, 1st relapse n = 3, 2nd relapse n = 5), steroids, caplacizumab, and rituximab	Two relapses
Hindilerden et al. [1]	Female/74	Concomitant	Positive	Mild	PEX (n = 11) Steroids	Lethargy − resolved
Albiol et al. [2]	Female/57	Concomitant	Negative (referred to as false negative, followed by positive serology)	Mild	Steroids, intravenous immunoglobulin PEX (n = 7)	Uneventful
Capecchi et al. [3] Female/55	Relapsed TTP following recovery from SARS CoV-2	Negative (positive serology suggesting a recent infection)	Mild Severe post-COVID pulmonary complications	Plasma infusion PEX (n = 14) Steroids caplacizumab	Severe neurological symptoms, multi-organ failure, DIC Intracranial hemorrhage

iTTP, immune thrombotic thrombocytopenic purpura.